In summary, although there is no definitive cure yet, the use of anti-VEGF treatment for secondary CNV has provided the opportunity to maintain functional vision in individuals with SFD, provided CNV is detected and treated early. The gene discussed is VEGFA; the disease is Sorsby fundus dystrophy.